Navigation Links
Micromet Has Started a New Phase 2 Trial with Adecatumumab in Colorectal Cancer Patients
Date:3/23/2009

with offices in Bethesda, MD and Munich, Germany. The Company is focused on developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases. The Company's novel antibody technology is based on its proprietary BiTE(R) antibody platform, representing a new class of antibodies that specifically activate T cells from the patient's own immune system to eliminate cancer cells or other disease related cells. Four of the Company's antibodies are currently in clinical trials, with the remainder of its product pipeline in preclinical development. The Company's lead program is a BiTE antibody known as blinatumomab, or MT103. It is in a phase 2 clinical trial for the treatment of patients with acute lymphoblastic leukemia and a phase 1 clinical trial for the treatment of patients with non-Hodgkin's lymphoma. Micromet's second BiTE antibody in clinical development is MT110, which targets the epithelial cell adhesion molecule (EpCAM). The Company owns all rights to MT110, which is currently in a phase 1 clinical trial for the treatment of patients with solid tumors. The Company's third clinical stage antibody is adecatumumab, also known as MT201, a traditional human monoclonal antibody that targets EpCAM-expressing solid tumors. Micromet is developing adecatumumab in collaboration with Merck Serono in a phase 1b clinical trial evaluating adecatumumab in combination with docetaxel for the treatment of patients with metastatic breast cancer. Micromet licensed a fourth clinical stage antibody, MT293, to TRACON Pharmaceuticals, Inc. MT293 is being developed in a phase 1 clinical trial for the treatment of patients with cancer. The Company's preclinical programs include MT203 being developed in collaboration with Nycomed. MT203 is a traditional human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of inflammatory and autoimmune diseases, such as
'/>"/>
SOURCE Micromet, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Micromet Key Events for 2009
2. Micromet Expands Committed Equity Financing Facility to $75 Million
3. Micromet Presents Data at the 23rd Annual Meeting of the International Society for Biological Therapy of Cancer on the Activity of Human Antibody Adecatumumab against KRAS-mutated Colon Cancer Cells
4. Micromet Presents Data at ESMO 2008 on Anti-EpCAM Antibody Adecatumumab (MT201) in Combination with Chemotherapy
5. Micromet, Inc. to Host Webcast and Conference Call to Discuss Blinatumomab Data Published in SCIENCE
6. Micromet, Inc. to Host Conference Call and Webcast to Discuss Second Quarter 2008 Financial Results
7. Micromet and Nycomed Begin Formal Preclinical Safety Studies for Antibody MT203 for Inflammatory and Autoimmune Diseases
8. Micromet and MedImmune Commence Treatment in Phase 2 Trial of BiTE Antibody Blinatumomab (MT103/MEDI-538) in Patients with Acute Lymphoblastic Leukemia
9. Micromets BiTE Antibody Blinatumomab (MT103/MEDI-538) Demonstrates Durable Responses in Patients with Relapsed Non-Hodgkins Lymphoma
10. Micromet to Present Clinical Update for BiTE Antibody MT103/MEDI-538 at the International Conference on Malignant Lymphomas
11. Micromet Enrolls First Patient in a Phase 1 Clinical Trial with MT110, the First BiTE Antibody for Treatment of Solid Tumors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/29/2014)... 2014 Kush Bottles, North America,s ... and consulting services for the medical and recreational marijuana ... has assumed the role of Chief Executive Officer. ... and worked as COO until February of 2014, returned ... other ventures. His return marks a clear dedication to ...
(Date:9/29/2014)... Tianyin Pharmaceutical Co., Inc. (NYSE Amex: ... specializes in patented biopharmaceutical, modernized traditional Chinese medicine ... today announced that its Qionglai Facility (QLF) has ... China Food & Drug Administration,s (CFDA) for its ... early September 2014, the Company has submitted the ...
(Date:9/29/2014)... and CAMBRIDGE, Mass. ... Solutions and KEW Group, Inc. (KEW), a privately ... for the two companies to make KEW,s state-of-the-art ... customers. KEW is a privately held ... cancer care by empowering all oncologists to access ...
Breaking Medicine Technology:Kush Bottles Co-Founder Steps into Role of CEO 2TPI's QLF Completes GMP site inspection by CFDA 2TPI's QLF Completes GMP site inspection by CFDA 3Cardinal Health Specialty Solutions, KEW Group Bring Power of Personalized Medicine to Community Oncologists 2Cardinal Health Specialty Solutions, KEW Group Bring Power of Personalized Medicine to Community Oncologists 3Cardinal Health Specialty Solutions, KEW Group Bring Power of Personalized Medicine to Community Oncologists 4
... Oslo Cancer Cluster represents a strong R&D environment dedicated ... lies within developing novel technologies and significantly better cancer ... Oslo Cancer Cluster is a research and ... accelerating the development of new cancer diagnostics and medicines. ...
... 31, 2011 Menicon Holdings BV and Eye Shelter ... France-based independent ophthalmic group, announced on October 31 that ... market the SOLO-care (R) contact lens solutions range in ... The agreement will enable Menicon to significantly ...
Cached Medicine Technology:Expanding Norwegian Cluster of Excellence Dedicated to Oncology 2Expanding Norwegian Cluster of Excellence Dedicated to Oncology 3Menicon to Market Eye Shelter's SOLO-care (R) Contact Lens Solution Range in Europe and Canada 2
(Date:9/29/2014)... (PRWEB) September 30, 2014 NAPW ... Clinical Manager Specialist, as a 2014 Professional Woman of ... distinction for leadership in clinical care. As the largest ... virtually every industry and profession, the National Association of ... over 600,000 members and nearly 300 Local Chapters. , ...
(Date:9/29/2014)... Every autumn, as high school and college gets ... takes off! Athletes typically train throughout the summer in ... the leading compression apparel company, makes the best ... for cross country running. , The compression leg ... muscle soreness (DOMS) throughout training in addition to speeding ...
(Date:9/29/2014)... 2014 China’s regulatory framework for ... country’s new leaders have recognized that the regulations ... are far from perfect along with rapid population ... years. Chinese state council issued the latest “Regulations ... on February 12, 2014, and it has come ...
(Date:9/29/2014)... (PRWEB) September 29, 2014 Leading Conejo ... (PMIR) and Thousand Oaks Surgery Center (TOSC) –– are ... a state-of-the-art healthcare facility in Thousand Oaks, Calif. The ... practices that offer Conejo Valley residents greater access to ... and chronic pain, while TOSC physicians are setting the ...
(Date:9/29/2014)... The Pulmonary Hypertension Association ... Centers (PHCC) in a program that seeks to ... of patients with pulmonary hypertension (PH), specifically pulmonary arterial ... the lungs that affects the functioning of the heart ... mean survivability is only 2.8 years. , Despite medical ...
Breaking Medicine News(10 mins):Health News:National Association of Professional Women Announces Sarah Shiermeister, Clinical Manager Specialist at Gentiva Health Services, a 2014 Professional Woman of the Year 2Health News:Muscle Support and Style With New Compression Leg Sleeves For Cross Country Runners 2Health News:Chinese Regulations on In-Vitro Diagnostic Reagents Market: Application & Approval 2014 Edition New Study Now Available at MarketReportsOnline.com 2Health News:Chinese Regulations on In-Vitro Diagnostic Reagents Market: Application & Approval 2014 Edition New Study Now Available at MarketReportsOnline.com 3Health News:Chinese Regulations on In-Vitro Diagnostic Reagents Market: Application & Approval 2014 Edition New Study Now Available at MarketReportsOnline.com 4Health News:New Thousand Oaks Medical Facility Hosts Grand Opening Event: Two Practices, One Celebration 2Health News:New Thousand Oaks Medical Facility Hosts Grand Opening Event: Two Practices, One Celebration 3Health News:Pulmonary Hypertension Association Accredits First Six PH Care CentersApplication Process Now Open 2Health News:Pulmonary Hypertension Association Accredits First Six PH Care CentersApplication Process Now Open 3Health News:Pulmonary Hypertension Association Accredits First Six PH Care CentersApplication Process Now Open 4
... Society for Technology in Anesthesia Annual Meeting Quantifies ... Improved ICU UtilizationIRVINE, Calif., Jan. 20 Masimo ... Pulse CO-Oximetry and Measure-Through Motion and Low Perfusion ... clinicians at Dartmouth-Hitchcock Medical Center (DHMC) presented new ...
... its 2008 distributions as follows:, Security Description: Common Stock, ... Ticker Symbol: BMR, ... Total ... Ordinary, Date Date ...
... clients in these tough economic times. , ... Wayne, NJ (PRWEB) January ... being hit hard. To succeed, CMS, a leader in the staffing ... moves such as utilizing the temporary workforce. , ,By ...
... 19 Anyone who has gone through,finding a long-term ... is,to search for and find a care facility such ... know how senior living can be expensive and stressful,trying ... and meets the,financial demands of senior citizens without knowing ...
... operation differ about 20% of the time, researchers say ... severe osteoarthritis tend to be happier with their care ... providers on the issue of total knee replacement, a ... patients don,t agree with providers when it comes to ...
... recommended care did better, regardless of race, study found ... between white and black patients with early-stage lung cancer ... a U.S. study that included nearly 18,000 patients. ... (pulmonary resection) provides the best chance of a cure ...
Cached Medicine News:Health News:Clinicians at Dartmouth-Hitchcock Medical Center Present New Data Showing Masimo Rainbow SET(R) Oximetry and Patient SafetyNet(TM) Improves Patient Outcomes and Reduces the Cost of Care 2Health News:Clinicians at Dartmouth-Hitchcock Medical Center Present New Data Showing Masimo Rainbow SET(R) Oximetry and Patient SafetyNet(TM) Improves Patient Outcomes and Reduces the Cost of Care 3Health News:Clinicians at Dartmouth-Hitchcock Medical Center Present New Data Showing Masimo Rainbow SET(R) Oximetry and Patient SafetyNet(TM) Improves Patient Outcomes and Reduces the Cost of Care 4Health News:Clinicians at Dartmouth-Hitchcock Medical Center Present New Data Showing Masimo Rainbow SET(R) Oximetry and Patient SafetyNet(TM) Improves Patient Outcomes and Reduces the Cost of Care 5Health News:Clinicians at Dartmouth-Hitchcock Medical Center Present New Data Showing Masimo Rainbow SET(R) Oximetry and Patient SafetyNet(TM) Improves Patient Outcomes and Reduces the Cost of Care 6Health News:Clinicians at Dartmouth-Hitchcock Medical Center Present New Data Showing Masimo Rainbow SET(R) Oximetry and Patient SafetyNet(TM) Improves Patient Outcomes and Reduces the Cost of Care 7Health News:BioMed Realty Trust Announces Tax Treatment of 2008 Distributions 2Health News:BioMed Realty Trust Announces Tax Treatment of 2008 Distributions 3Health News:CMS Staffing Announces a its New and Revolutionary Consultative Approach With Clients 2Health News:Raising the Quality of Long-Term Care for Seniors 2Health News:Raising the Quality of Long-Term Care for Seniors 3Health News:Knee Replacement Works Best When Patients, Providers Agree 2Health News:Optimal Treatment Boosts Blacks' Lung Cancer Survival 2
The 6.5mm cannulated cancellous ACE SCFE Screw is specifically designed for the treatment of slipped capital femoral epiphysis. The ACE SCFE Screw simplifies insertion and facilitates removal....
Smith & Nephew offers a wide variety of cannulated screw products. Most screw sizes are available in both partially threaded and fully threaded versions. , ,All systems optimize implant strength with...
... Humeral Nail enables fixation of humeral shaft ... may be associated with antegrade nailing. , ... distal interlocking using a nail-mounted targeting device. ... with the patient in the prone position. ...
... leading medical technology company and a ... more than a decade, introduces a ... ACT Plus System is a microprocessor-controlled ... coagulation endpoints in whole blood, citrated ...
Medicine Products: